JUNSHI BIO (01877) signed a distribution and commercialization agreement with LEO Pharma for Teriparatide Monoclonal Antibody.

JUNSHI BIO (01877) announced that recently, its wholly-owned subsidiary TopAlliance Biosciences Inc. signed a Distribution and Commercialization Agreement with LEO Pharma A/S. According to the agreement, the company will grant LEO Pharma the exclusive rights to store, distribute, promote, market, and sell TROP2 antibody in all existing and future member states of the European Union (EU) and the European Economic Area (EEA), as well as in Switzerland, the United Kingdom. Under the agreement, LEO Pharma will make an upfront payment of 15 million Euros to TopAlliance Biosciences. The exclusive rights will not take effect until the upfront payment is fully paid. If both parties wish to collaborate on additional indications for TROP2 antibody in the cooperation region, they shall reach an agreement on any milestone payments to be made to TopAlliance Biosciences. LEO Pharma will also pay TopAlliance Biosciences a double-digit percentage of net sales of TROP2 antibody in the cooperation region. The announcement stated that this collaboration is an important practice of the company's internationalization strategy of "rooted in China, global layout," and is also an important step for TopAlliance Biosciences to expand its business in the European market. The company will work together with partner LEO Pharma to actively prepare for the commercialization of TROP2 antibody in the European region, leveraging LEO Pharma's mature drug distribution network and extensive market promotion experience in the European market. The TROP2 antibody will be able to accurately and efficiently cover patients in the cooperation region, significantly reducing the market introduction period and providing high-quality treatment options for patients in the European region. This transaction will also enhance the product and company's brand influence globally, further expanding the company's global commercialization network layout. This transaction is expected to have a positive impact on the company's continued operations.